Androgen/AR signaling is widely recognized as a critical driver of hormone-related malignancies, particularly prostate cancer in which AR activation is a key oncogenic driver, and androgen deprivation therapy (ADT) remains a cornerstone of treatment (6). This evidence concerns the gene AR and Familial prostate cancer.